BeiGene reports immune events in Phase Ib for B cell cancer combo

BeiGene Ltd. (NASDAQ:BGNE) reported three immune-related events in an Australian Phase Ib trial of zanubrutinib (BGB-3111) plus tislelizumab (BGB-A317) to treat B cell malignancies at the American Society of Hematology meeting in Atlanta. Zanubrutinib is a selective oral Bruton’s tyrosine kinase (Btk) inhibitor and tislelizumab is a humanized IgG4

Read the full 497 word article

User Sign In